Improving Cancer Treatment with 5'd-FUR
Author Information
Author(s): G.J. Peters, B.J.M. Braakhuis, E.A. de Bruijn, E.J. Laurensse, M. van Walsum, H.M. Pinedo
Primary Institution: Free University Hospital, Amsterdam, The Netherlands; University of Antwerp, Belgium
Hypothesis
Can the prodrug 5'd-FUR enhance the therapeutic efficacy of 5-FU in resistant head and neck tumors?
Conclusion
The study found that 5'd-FUR can enhance the sensitivity of certain 5-FU resistant tumors, leading to improved therapeutic efficacy.
Supporting Evidence
- 5'd-FUR showed increased therapeutic efficacy compared to 5-FU in certain tumor lines.
- Colon 26 and HNX-KE tumors had a high activity of OPRT, correlating with sensitivity to 5'd-FUR.
- 5'd-FUR can be administered at much higher doses than 5-FU with lower toxicity.
Takeaway
This study shows that a drug called 5'd-FUR can help treat some cancers that don't respond well to another drug called 5-FU.
Methodology
The study tested four human head and neck xenograft tumor lines and two murine colon carcinomas for their sensitivity to 5-FU and 5'd-FUR, measuring enzyme activities and plasma pharmacokinetics.
Limitations
The study was limited to specific tumor lines and may not generalize to all cancer types.
Participant Demographics
The study involved human head and neck cancer xenografts and murine colon carcinomas.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website